Clinical trial
Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors
NCT00066651 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00066651 |
|---|---|
| Title | Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors |
| Official title | Phase I Study Of SS1(dsFv)-PE38 Anti-Mesothelin Immunotoxin In Advanced Malignancies: I.V. Infusion QOD Dosing |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Malignant Mesothelioma, Ovarian Cancer, Pancreatic Cancer, Primary Peritoneal Cavity Cancer |
| Intervention type | Biological |
| Interventions | SS1(dsFv)-PE38 immunotoxin |
| Start date | Jul 1, 2003 |
| First posted | Aug 7, 2003 |
| Last update posted | Apr 30, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: